NVO
NOVO NORDISK A S
NYSE: NVO · Bagsvaerd Denmark, G7 · Healthcare
$48.77+0.59 (+1.22%)Closed
Market Cap—
Cash—most recent
Runway—
P/E (TTM)—
52-Wk Range$34.76 – $68.39
Avg Volume18.4M3-month
Price & Trading Activity

Daily close with catalyst overlays and trading volume

$48.77-59.2%
Pipeline

Drug candidates sponsored by NOVO NORDISK A S · ClinicalTrials.gov

67 drugs · 100 trials
PhaseDrug / CandidateIndicationsStatusNext CompletionTrials
Phase 4Unnamed
Diabetes+2 more
Completed
2006-06past
1
Phase 4biphasic insulin aspart 30
Diabetes+1 more
Completed
2009-04past
2
Phase 4activated recombinant human factor VII
Congenital Bleeding Disorder+3 more
Completed
2011-10past
2
Phase 4insulin detemir
Diabetes+3 more
Completed
2015-05past
8
Phase 3estradiol, 25 mcg
Menopause+1 more
Terminated
2004-03-17past
1
Phase 3rosiglitazone
Diabetes+1 more
Terminated
2008-03-10past
1
Phase 3insulin aspart
Diabetes+2 more
Completed
2011-03past
2
Phase 3somatropin
Growth Hormone Disorder+5 more
Completed
2013-12past
3
Phase 3Faster-acting insulin aspart
Diabetes+1 more
Completed
2015-05-12past
2
Phase 3insulin degludec/liraglutide
Diabetes+1 more
Completed
2016-10-05past
1
Phase 3insulin degludec
Diabetes+3 more
Completed
2017-04-05past
5
Phase 3somapacitan
Growth Hormone Disorder+1 more
Completed
2018-10-04past
1
Phase 3liraglutide
Diabetes+4 more
Completed
2022-09-12past
6
Phase 3Cagrilintide
Obesity
Completed
2025-12-08past
1
Phase 3Ziltivekimab
Cardiovascular Risk+1 more
Recruiting
2026-12-14
1
Phase 3semaglutide
Diabetes+6 more
Active, not recruiting
2027-11-07
10
Phase 3zenagamtide
Overweight+1 more
Not yet recruiting
2028-06-27
1
Phase 3Etavopivat A
Sickle Cell Disease+1 more
Recruiting
2030-12-30
1
Phase 2recombinant interleukin-21
Cancer+1 more
Completed
2009-01-07past
1
Phase 2NNC0114-0006
Inflammation+1 more
Completed
2014-12past
1
Phase 2Concizumab
Haemostasis+2 more
Completed
2018-06-22past
2
Phase 2Semaglutide 2.4 mg
Diabetes Mellitus, Type 2
Completed
2022-07-07past
1
Phase 2NNC0480-0389
Diabetes Mellitus, Type 2
Completed
2023-02-13past
1
Phase 2NNC0194-0499
Alcohol-related Liver Disease
Completed
2025-11-21past
1
Phase 10.5 mg estradiol / 0.1 mg norethisterone acetate (NETA)
Menopause+1 more
Completed
2005-06past
1
Phase 1NNC 0070-0002-0349
Metabolism and Nutrition Disorder+1 more
Withdrawn
2009-12past
1
Phase 1catridecacog
Congenital Bleeding Disorder+2 more
Completed
2010-07past
1
Phase 1insulin degludec/insulin aspart
Diabetes+1 more
Completed
2010-11past
1
Phase 1NNC0114-0000-0005
Inflammation+2 more
Completed
2012-02past
1
Phase 1liraglutide-depot
Diabetes+2 more
Completed
2012-03past
1
Phase 1Norditropin® FlexPro® pen
Growth Disorder+1 more
Completed
2013-10past
1
Phase 1NNC0113-0987
Diabetes+1 more
Completed
2014-07past
1
Phase 1SNAC
Healthy
Completed
2017-05-04past
1
Phase 1NNC0143-0406
Diabetes+1 more
Completed
2017-06-17past
2
Phase 1Insulin icodec
Diabetes+1 more
Completed
2017-12-12past
1
Phase 1NNC9204-1706
Metabolism and Nutrition Disorder+1 more
Completed
2019-09-05past
1
Phase 1NNC0519-0130
Healthy Volunteers (Diabetes Mellitus, Type 2)
Completed
2024-04-02past
1
Phase 1Etavopivat
Healthy Volunteers+2 more
Completed
2024-10-31past
1
Phase 1NNC0487-0111 (formulation D)
Obesity+1 more
Completed
2025-06-05past
1
Phase 1NNC0174-1213 A
Obesity+1 more
Recruiting
2026-03-26past
1
Phase 1NNC0363-1063
Diabetes Mellitus, Type 1
Completed
2026-04-21past
1
Phase 1NNC0442-0344 A
Haemophilia A
Completed
2026-05-08past
1
Early Phase 1Heparin
Healthy Volunteers
Completed
2022-01-11past
1
N/Asoluble human insulin
Diabetes+1 more
Completed
2006-05past
1
N/Abiphasic insulin aspart
Diabetes+1 more
Completed
2008-11-15past
1
N/Arepaglinide
Diabetes+1 more
Completed
2009-03past
1
N/Ahuman insulin
Diabetes+1 more
Completed
2009-12past
1
N/Aeptacog alfa (activated)
Congenital Bleeding Disorder+2 more
Completed
2011-08past
1
N/AUnnamed
Diabetes+1 more
Completed
2013-11past
1
N/AUnnamed
Diabetes+1 more
Completed
2014-03past
1
N/AUnnamed
Diabetes+3 more
Completed
2015-10past
1
N/AUnnamed
Growth Hormone Disorder+1 more
Completed
2015-12past
1
N/AUnnamed
Diabetes+2 more
Completed
2016-08-12past
1
N/AUnnamed
Growth Hormone Deficiency in Children
Completed
2019-04-25past
1
N/Aturoctocog alfa
Congenital Bleeding Disorder+1 more
Completed
2021-06-16past
1
N/AUnnamed
Haemophilia A+3 more
Completed
2021-10-25past
1
N/ASaxenda®
Obesity or Overweight
Completed
2022-04-15past
1
N/AIDegLira
Diabetes Mellitus, Type 2
Completed
2022-10-26past
1
N/AUnnamed
Atherosclerotic Cardiovascular Disease (ASCVD)+1 more
Completed
2023-05-15past
1
N/AUnnamed
Type-2 Diabetes Mellitus (T2DM)
Completed
2024-04-29past
1
N/AUnnamed
Atherosclerotic Cardiovascular Disease (ASCVD)+2 more
Completed
2024-05-10past
1
N/AUnnamed
Obesity+1 more
Completed
2024-06-24past
1
N/AUnnamed
Overweight+1 more
Completed
2025-08-25past
1
N/AUnnamed
Haemophilia
Enrolling
2025-12-19past
1
N/AUnnamed
Diabetes Mellitus, Type 2
Recruiting
2026-07-01past
1
N/ATuroctocog alfa pegol (N8-GP)
Haemophilia A
Enrolling
2027-06-03
1
N/ANorditropin® FlexPro®
Growth Hormone Deficiency in Children+1 more
Enrolling
2029-06-30
1
Valuation

Risk-adjusted NPV

Loading pipeline…
Peer comparison

Cohort check

No peer cohort defined for NVO. Cohorts currently cover gene editing, mRNA, rare-disease gene therapy, and large-cap biotech — more coming soon.